Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sorenson, E. J.
Right arrow Articles by Stevens, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sorenson, E. J.
Right arrow Articles by Stevens, J. C.
Related Collections
Right arrow All Health Services Research
Right arrow Prognosis
Right arrow Amyotrophic lateral sclerosis
Right arrowRelated Article
NEUROLOGY 2007;68:600-602
© 2007 American Academy of Neurology

Effect of referral bias on assessing survival in ALS

Eric J. Sorenson, MD, Jayawant Mandrekar, PhD, Brian Crum, MD and J. Clarke Stevens, MD

From the Departments of Neurology (E.J.S., B.C., J.C.S.) and Biostatistics (J.M.), Mayo Clinic, Rochester, MN.

Address correspondence and reprint requests to Dr. Eric J. Sorenson, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905; e-mail: sorenson.eric{at}mayo.edu

We assessed the effect of referral bias on patients with ALS treated at our medical center. A total of 132 subjects were treated by our center over the past 3 years. The referral population had a median survival of 29 months compared to 18 months for the local population (p = 0.007). Referral bias should be addressed when assessing the efficacy of self-selected therapies in the setting of a tertiary ALS clinic.

Disclosure: The authors report no conflicts of interest.

Received July 7, 2006. Accepted in final form October 23, 2006.


Related Article

February 20 Highlights
Neurology 2007 68: 540-541. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 JCOHome page
L. Pusztai, K. Broglio, F. Andre, W. F. Symmans, K. R. Hess, and G. N. Hortobagyi
Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor-Positive Breast Cancer
J. Clin. Oncol., October 1, 2008; 26(28): 4679 - 4683.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. Logroscino, E. Beghi, O. Hardiman, A. Chio, J. D. Mitchell, R. J. Swingler, B. Traynor, for EURALS, E. J. Sorenson, J. Mandrekar, et al.
EFFECT OF REFERRAL BIAS ON ASSESSING SURVIVAL IN ALS
Neurology, August 28, 2007; 69(9): 939 - 940.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

Effect of referral bias on assessing survival in ALS
Giancarlo Logroscino, et al.
Neurology Online, 24 May 2007 [Full text]
Reply from the Authors
Eric J. Sorenson, et al.
Neurology Online, 24 May 2007 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.